Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.04 USD

1.04
73,101

0.00 (0.00%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.05 +0.01 (0.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amedisys (AMED) Poised on Strong Home Health, Risks Remain

by Zacks Equity Research

On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).

    QIAGEN Releases Favorable GeneReader Results, Expands in NGS

    by Zacks Equity Research

    QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

      Enzo Biochem Stock: 3 Reasons Why ENZ Is a Top Choice for Momentum Investors

      by Zacks Equity Research

      Let's focus on Enzo Biochem, Inc. (ENZ) as this momentum stock is looking especially impressive right now.

        Earnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy?

        by Zacks Equity Research

        Enzo Biochem (ENZ) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

          Enzo Biochem (ENZ) Shares March Higher, Can It Continue?

          by Zacks Equity Research

          As of late, it has definitely been a great time to be an investor in Enzo Biochem, Inc. (ENZ).

            Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%

            by Zacks Equity Research

            Enzo Biochem, Inc. (ENZ) shares rose above 5% in the last trading session.

              Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss

              by Zacks Equity Research

              Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.

                Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

                by Zacks Equity Research

                Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

                  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View

                  by Zacks Equity Research

                  GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.

                    GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

                    by Zacks Equity Research

                    GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.

                      Mallinckrodt (MNK) Tops on Earnings in Transition Quarter

                      by Zacks Equity Research

                      Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.

                        ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

                        by Zacks Equity Research

                        ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

                          Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

                          by Zacks Equity Research

                          Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

                            Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y

                            by Zacks Equity Research

                            Novo Nordisk A/S (NVO) reported fourth-quarter 2016 earnings of 50 cents per American Depository Receipt (ADR), missing the Zacks Consensus Estimate of 52 cents by 3.8%.

                              AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                              by Zacks Equity Research

                              AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                                BioMarin's Hemophilia Candidate Included in PRIME Initiative

                                by Zacks Equity Research

                                BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).

                                  AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

                                  by Zacks Equity Research

                                  AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

                                    Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session

                                    by Zacks Equity Research

                                    Seres Therapeutics, Inc. (MCRB) shares rose over 5% in the last trading session.

                                      Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval

                                      by Zacks Equity Research

                                      Endo International plc (ENDP) announced that Par Pharmaceutical has received final approval from the FDA regarding its New Drug Application (NDA) for ephedrine sulfate injection.

                                        Novo Nordisk Inks Diabetes Deal with University of Oxford

                                        by Zacks Equity Research

                                        Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.

                                          AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA

                                          by Zacks Equity Research

                                          AstraZeneca (AZN) announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol.

                                            Immunogen Doses First Patient in Ovarian Cancer Drug Study

                                            by Zacks Equity Research

                                            ImmunoGen, Inc. (IMGN) announced that the first patient has been dosed in FORWARD I, the company's phase III study, assessing mirvetuximab soravtansine, as a single-agent therapy for the treatment of platinum-resistant ovarian cancer.

                                              Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                                              by Zacks Equity Research

                                              Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

                                                Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher

                                                by Zacks Equity Research

                                                Clovis Oncology, Inc. (CLVS) saw its shares rise above 5% in the last trading session.

                                                  Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

                                                  by Zacks Equity Research

                                                  Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.